The World of Health & Medicine News

Investors managing $11.5 trillion urge food companies to diversify away from animal proteins

Investors managing $11.5 trillion urge food companies to diversify away from animal proteins

 Investors managing $11.5 trillion in assets are calling on major food companies and retailers to diversify into more plant-based protein sources to enhance supply chain resiliency and mitigate food security risks.

As global interest rates and prolonged higher temperatures help lift feed costs, and with prices for products such as eggs susceptible to unpredictable bird flu outbreaks, food companies are facing increasingly brittle animal supply chains and risk investor divestment should their exposure be deemed too high.

A group of 73 investors engaging in the Farm Animal Investment Risk and Return Initiative investor network are calling on manufacturers and retailers to seize the “growth and health” opportunities alternative protein sources present, according to a FAIRR report set for publication on Tuesday.

Through FAIRR, the investors have engaged with 20 companies, including manufacturers Nestle, Danone and Kraft Heinz and retailers Amazon, Carrefour and Walmart.

“For food and retail, protein diversification is a key element to reduce your CO2 emissions,” Sophie Kamphuis, senior advisor for responsible investment at Dutch asset manager MN, told Reuters.

“We like it if companies set sales targets and launch products, but we also want that to be replacing animal proteins,” Kamphuis added, naming Ahold Delhaize’s (AD.AS), opens new tab target for its European retailers – committing to 50% of proteins sold being plant-based by 2030 – as a good example.

Private investment in non-meat protein sources, such as beans, pulses, plant-based alternatives to animal products and novel methods like cell cultivation, fell to just over $1 billion last year, from a spike of almost $7 billion in 2021, according to The Good Food Institute.

When it comes to protein diversification that focuses on meat substitutes, the recurring problem has been that the products are just not good enough, Jo Raven, director of thematic research and corporate innovation at FAIRR, told Reuters.

“The reality is they did not get the taste and texture right, and consumers are fickle creatures,” Raven said. “So if they purchase it once and just didn’t like it, they’re going to be a harder group to convince otherwise.”

spot_img

Explore more

spot_img

US CDC ends guidance that all newborns should get hepatitis B...

US CDC ends guidance that all newborns should get hepatitis B vaccine, in major policy shift The U.S. Centers for Disease Control and Prevention on...

FDA Approves J&J’s Akeega for Expanded Use in Prostate Cancer

FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer Johnson & Johnson JNJ announced that the FDA approved its precision therapy, Akeega (niraparib and abiraterone acetate...

Women are increasingly using steroids — despite these 7 major risks

Women are increasingly using steroids — despite these 7 major risks As fitfluencers push powerlifting, weight training and “whatever it takes” to get toned, more women...

Kyverna’s cell therapy helps patients improve mobility in mid-stage trial

Kyverna's cell therapy helps patients improve mobility in mid-stage trial Kyverna Therapeutics said its experimental cell therapy met the main goal of “significantly” improving patients’...

AstraZeneca, Daiichi’s breast cancer drug gets FDA nod as first-line treatment

AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment The U.S. Food and Drug ​Administration has approved ‌Daiichi Sankyo's therapy in combination ‌with...

WHO expert group’s new analysis reaffirms there is no link between...

WHO expert group’s new analysis reaffirms there is no link between vaccines and autism new analysis from a WHO global expert committee on vaccine safety...

US FDA expands use of GSK’s Blujepa as treatment for gonorrhea

US FDA expands use of GSK's Blujepa as treatment for gonorrhea The U.S. Food and Drug Administration said on Thursday it has expanded the use...

WHO chief still hopes Trump administration will rethink withdrawal

WHO chief still hopes Trump administration will rethink withdrawal The World Health Organization chief said on Thursday that he was still hoping the U.S. administration...